Human uPAR (aa 51-156) Control Fragment Recombinant Protein | Invitrogen RP-102358 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

protein

product name :

Human uPAR (aa 51-156) Control Fragment Recombinant Protein

catalog :

RP-102358

quantity :

100 uL

price :

US 259.00

product information

Product Type :

Protein

Product Name :

Human uPAR (aa 51-156) Control Fragment Recombinant Protein

Catalog # :

RP-102358

Quantity :

100 uL

Price :

US 259.00

Clonality :

Recombinant

Purity :

purified

Reactivity :

Human

Applications :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Species :

Human

Storage :

-20 C, Avoid Freeze/Thaw Cycles

Description :

The urokinase-type plasminogen activator receptor is a key molecule in the regulation of cell-surface plasminogen activation and plays an important role in many normal as well as pathologic processes. The human PLAUR cDNA encodes 335 amino acids including a predicted signal peptide of 22 residues and a hydrophobic C-terminal portion. It produces a highly glycosylated protein of about 50 kD in monocytes where it is anchored to the plasma membrane by glycosyl-phosphatidylinositol linkage. PLAUR, also known as UPAR, is directly associated with the carbohydrate-binding domain of SELL in the membrane of neutrophils, an association analogous to that between PLAUR and beta-2 integrins. PLAUR-mediated calcium mobilization is SELL dependent. UPAR mRNA levels correlate with the invasive potential of endometrial carcinomas and show a 33-fold increase in UPAR mRNA levels in advanced clinical stage endometrial tumors compared with normal endometrial tissue. Furthermore, the increase in UPAR mRNA levels correlated linearly with the progression of disease stage. UPAR protein expressioin correlated positively with rate of recurrence and mortality in patients with endometrial cancer. UPAR appears to be a useful prognostic marker for advanced endometrial cancer.

Format :

Liquid

Applications w/Dilutions :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Aliases :

Cd87; MO3; Monocyte activation antigen Mo3; Par; plasminogen activator urokinase receptor 3; plasminogen activator, urokinase receptor; PLAUR; Plaur3; sCD87; soluble CD87; uPAR; U-PAR; uPAR-2; uPAR-3; u-plasminogen activator receptor form 2; urinary plasminogen activator receptor 2; urinary plasminogen activator receptor 3; URKR; urokinase plasminogen activator receptor; urokinase plasminogen activator surface receptor; urokinase-type plasminogen activator (uPA) receptor; urokinase-type plasminogen activator receptor